ArticleCureus2024
Immune-Mediated Necrotizing Myopathy With Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) Antibodies Following Viral Infection and Without Association With Statin Use: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report - Anti-HMGCR-Associated Immune-Mediated Necrotizing Myopathy and Interstitial Lung Disease With Long-Term Use of Ezetimibe and Low-Dose Atorvastatin.International journal of rheumatic diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated necrotizing myopathy (IMNM) is a rare form of inflammatory myopathy characterized by severe muscle weakness, elevated serum creatine kinase (CK) levels, and myofiber necrosis with minimal inflammatory infiltrates. IMNM is frequently associated with autoantibodies, particularly anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and is often linked to statin use. However, it can also develop in statin-naïve patients, especially following viral infections. We present the case of a 47-year-old woman who developed anti-HMGCR-positive IMNM without prior statin exposure, following a viral respiratory infection and subsequent dengue fever. She initially presented with proximal muscle weakness and elevated CK levels, which worsened after contracting dengue. Diagnostic testing confirmed the presence of anti-HMGCR antibodies, and a muscle biopsy revealed necrotizing myopathy. Treatment with methylprednisolone, intravenous immunoglobulin, and rituximab resulted in significant clinical improvement. This case underscores the need to consider IMNM in patients with unexplained muscle weakness and elevated CK levels, even in the absence of statin use. Viral infections may trigger IMNM, highlighting the importance of early recognition and aggressive immunosuppressive therapy to prevent severe complications. Further research is required to better understand the pathophysiology of IMNM and optimize treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.